|
|
|
|
|
|
|
|
|
|
"Pazopanib therapy in combination with metronomic topotecan therapy showed significant antitumor and antiangiogenic properties in preclinical ovarian cancer models and warrants further investigation as a novel therapeutic regimen in clinical trials."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.